Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/32134
Title: Tuberculosis-HIV treatment with Rifampicin or Rifabutin: are the outcomes different?
Authors: Schmaltz, Carolina Arana Stanis
Demitto, Fernanda de Oliveira
Sant’Anna, Flavia Marinho
Rolla, Valeria Cavalcanti
Affilliation: Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em Micobactérias. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em Micobactérias. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em Micobactérias. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em Micobactérias. Rio de Janeiro, RJ, Brasil.
Abstract: BACKGROUND: Rifamycins are a group of antibiotics mainly used in the treatment of tuberculosis (TB), however they interactwith antiretroviral therapy (ART). Rifabutin allows more regimens options for concomitant imunodeficiency virus (HIV) treatment compared to rifampicin. OBJECTIVE: Compare the outcomes of TB-HIV co-infected patients who used rifampicin or rifabutin. METHODS: We analysed data from a prospective cohort study at National Institute of Infectious Diseases Evandro Chagas, Rio de Janeiro (RJ), Brazil. Patients who were treated for TB and HIV with rifampicin or rifabutin, from February 2011 to September 2016 were included. FINDINGS: There were 130 TB-HIV patients, of whom 102 were treated with rifampicin and 28 with rifabutin. All patients in the rifabutin-treated group and 55% of the rifampicin-treated group patients were ART-experienced. Patients treated with rifampicin had similar abandon and cure rates, interruptions in treatment due to adverse reactions, immune reconstitution inflammatory syndrome and a similar mortality rate as those treated with rifabutin. However, rifampicin-treated patients had higher CD4 counts and more frequently undetectable HIV viral load by the end of treatment (67% versus 18%, p < 0.001) compared to rifabutin-treated patients, even when only ART-experienced patients were evaluated (66,6% versus 36,3%, p = 0.039). CONCLUSIONS Patients who used rifabutin had worst immune and virological control. This group had more ART-experienced patients. New and simpler regimens are needed for patients who do not respond to previous antiretroviral therapies.
Keywords: Tuberculosis
HIV
Rifampicin
Rifabutin
Rifamycin
Outcomes
Issue Date: 2019
Publisher: Instituto Oswaldo Cruz
Citation: SCHMALTZ, Carolina Arana Stanis et al. Tuberculosis-HIV treatment with Rifampicin or Rifabutin: are the outcomes different? Memórias do Instituto Oswaldo Cruz, Rio de Janeiro, v. 114, p. 1-5, 2019.
DOI: 10.1590/0074-02760180420
ISSN: 0074-0276
Copyright: open access
Appears in Collections:INI - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
ve_Schmaltz_Carolina_etal_INI_2019.pdf261.23 kBAdobe PDFView/Open



FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.